http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 11 Aug 2026 12:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Press+Releases/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. </p><p> Dr Kim will engage with investors in a fireside discussion led by Piper Sandler analysts at 12:30 p.m. ET virtually. </p><p> One-on-one meetings may be scheduled directly with Medincell. </p><p> <b>About Medincell</b> </p><p> Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative http://www.streetinsider.com/Business+Wire/Medincell%E2%80%99s+Dr+Grace+Kim+to+Participate+in+Piper+Sandler+CNS+Symposium/26904194.html Tue, 11 Aug 2026 12:30:00 -0400 A.26800952 MEDCL O.00711722 O.01384798 http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Press+Releases/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html <p> MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously. </p><p> According to Teva, based on IQVIA1 data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers http://www.streetinsider.com/Business+Wire/UZEDY%C2%AE%3A+Record+Q2+Net+Sales+of+%2477M%2C+Up+43%25+YoY%3B+Teva+Raises+2026+Outlook/26830699.html Wed, 29 Jul 2026 07:42:00 -0400 A.06822034 A.26800952 A.27499954 A.50200193 MEDCL O.00401804 O.00448140 O.00711722 O.01384798 O.05029585 O.20026344 TEVA TEVA